CSPC Pharmaceutical Group’s Stock Price Soars to 7.96 HKD, Marking a 2.45% Uptick: A Healthy Investment Opportunity

CSPC Pharmaceutical Group (1093)

7.96 HKD +0.19 (+2.45%) Volume: 144.66M

CSPC Pharmaceutical Group’s stock price stands at 7.96 HKD, marking a positive trading session with a 2.45% increase and a robust trading volume of 144.66M. With a remarkable Year-to-Date (YTD) percentage change of +62.55%, CSPC Pharmaceutical Group (1093)’s stock performance continues to show promising growth.

Latest developments on CSPC Pharmaceutical Group

CSPC Pharmaceutical Group‘s stock price is expected to see movement today following key events leading up to this point. The company recently gained U.S. clinical trial approval for its siRNA drug, marking a significant milestone. Additionally, CSPC’s SYH-2056 has been given the green light to enter clinical trials in China for depression treatment, while its SYH2061 injection has received FDA approval for clinical trials. These developments in the pharmaceutical sector are expected to shape CSPC’s outlook, with investors eagerly awaiting pivotal data readouts. Despite a subdued performance in finished drugs in the past, Huatai Securities remains optimistic about CSPC Pharmaceutical Group, lowering the target price to HKD 12.75 but maintaining a “Buy” rating.

CSPC Pharmaceutical Group on Smartkarma

Analysts on Smartkarma, like Tina Banerjee, have been closely following CSPC Pharmaceutical Group‘s performance. In a recent report titled “CSPC Pharma (1093 HK): 9M25 Remain Subdued on Finished Drugs; Key Pivotal Data Read Outs Awaited,” it was highlighted that the company’s revenue dropped by 12% YoY primarily due to a decline in finished drugs sales. Despite this, the focus on new products and the high-end market is expected to drive future growth for CSPC Pharmaceutical Group.

Another report by Tina Banerjee, “CSPC Pharma (1093 HK): Finished Drugs Drag 1H25; 2H25 Expected To End with More Licensing Deals,” discussed how the company’s revenue dropped by 18.5% YoY in the first half of 2025. However, the outlook seems positive with upcoming collaborations and expansions into the high-end market. This move is anticipated to bring in more licensing deals and enhance future revenue visibility for CSPC Pharmaceutical Group.

A look at CSPC Pharmaceutical Group Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, CSPC Pharmaceutical Group seems to have a positive long-term outlook. With high scores in Dividend and Value, the company is seen as stable and offering good returns to investors. Additionally, its Resilience score indicates that it is well-equipped to weather economic downturns. However, the Growth and Momentum scores are slightly lower, suggesting that the company may not experience rapid expansion in the near future.

CSPC Pharmaceutical Group Limited is a pharmaceutical company that focuses on manufacturing and selling a variety of pharmaceutical products, including vitamin C, antibiotics, and generic drugs. In addition to its current product offerings, the company is also involved in the development of new and innovative drugs and antibiotics. Overall, CSPC Pharmaceutical Group appears to be a solid investment option, with its strong dividend and value scores reflecting its stability and potential for long-term growth.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma